Mark Foley Net Worth & Insider Trades

Mark Foley - CEO, Revance Therapeutics, Inc

As of July 5, 2022

What is Mark Foley's Net Worth?

The current estimated net worth of Revance Therapeutics, Inc's CEO, Mark Foley, is estimated to be about $42.62M . Mark Foley owns about 879,978 units of Revance Therapeutics, Inc common stock. In the last 5 years at Revance Therapeutics, Inc, Mark Foley has sold an estimated value of $6.45M worth.

What is Mark Foley's Past Insider Trading?

Mark Foley's largest purchase order was 20,000 units , worth over $539.17K on November 9, 2017. In total, Mark Foley has made about 15 transactions over 5 years of their time at Revance Therapeutics, Inc. Mark Foley usually trades in October, with the busiest year in 2021. The most recent transaction was a purchase order of 40,000 units , worth over $515.92K on November 29, 2021.

Ticker
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1

What was Mark Foley's Salary in 2020?

As CEO of Revance Therapeutics, Inc, Mark Foley has a total base salary of $650,000 . Mark Foley received compensation valued at about $8,780,936 in 2020 after becoming CEO. The vast majority of their compensation came in the form of stock awards of $7,794,350 , other earnings, plans or compensations of $328,331 , and other compensation of $8,255 .

What is Mark Foley's' Mailing Address?

  • Mailing address is Zeltiq Aesthetics Inc. 4698 Willow Road Suite 100 Pleasanton CA 94588 CA

Revance Therapeutics, Inc Executive Compensation

Name
Year
Salary
Bonus
Stock Awards
Option Awards
Other Earnings Plans or Compensations
Other Compensation
Total
Mark J. Foley 2020 $650,000 - $7,794,350 - $328,331 $8,255 $8,780,936
Mark J. Foley 2019 $189,764 $150,000 $11,728,370 $5,112,573 - $9,723 $17,190,430
Tobin C. Schilke 2020 $421,375 - $1,131,345 $1,273,662 $143,186 $11,531 $2,981,099
Tobin C. Schilke 2019 $407,126 $25,000 $86,150 $299,781 $178,123 $11,078 $1,007,258
Tobin C. Schilke 2018 $64,644 $25,000 $449,280 $1,434,350 - $233 $1,973,507
Abhay Joshi, Ph.D. 2020 $514,608 - $1,405,850 $1,913,759 $213,726 $11,731 $4,059,674
Abhay Joshi, Ph.D. 2019 $485,479 - $271,373 $939,314 $204,211 $9,520 $1,909,897
Abhay Joshi, Ph.D. 2018 $469,062 - $342,513 $1,192,465 $232,186 $9,210 $2,245,436
Dustin Sjuts 2020 $415,000 - $1,294,250 $1,306,320 $141,020 $66,242 $3,222,832
Dustin Sjuts 2019 $378,333 $50,000 $43,075 $99,927 $183,902 $45,786 $801,023
Dwight Moxie 2020 $370,104 $125,000 $1,309,383 $2,579,240 $125,426 $10,356 $4,519,508
No matching records found

Source: https://www.sec.gov/Archives/edgar/data/1479290/000147929021000089/rvncfy20proxystatementdef1.htm

What are Revance Therapeutics, Inc's Past Insider Trades?

Revance Therapeutics, Inc's most recent insider trade came on September 16, 2022 by Dwight Moxie who sold 11,000 units worth $297.8K . In the last 8 years, insiders at Revance Therapeutics, Inc have sold an estimated value of $30.1M and bought an estimated value of $8.63M worth of shares. Insider trading is most common in May, with the busiest year in 2021. The most active traders at the company are Daniel Browne, CEO and President,  Curtis Ruegg, EVP,  and Lauren Silvernail, CFO & CBO .

Revance Therapeutics, Inc. Insider Trades

Insider Names
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1